Human Metabolome Technologies Inc
TSE:6090
Intrinsic Value
Human Metabolome Technologies, Inc. engages in the business of diagnostic technology and medical products. [ Read More ]
The intrinsic value of one
Human Metabolome Technologies Inc
stock under the Base Case scenario is
544.08
JPY.
Compared to the current market price of 682 JPY,
Human Metabolome Technologies Inc
is
Overvalued by 20%.
Human Metabolome Technologies Inc's market capitalization is 4B JPY.
Human Metabolome Technologies Inc stock price is 682 JPY.
Human Metabolome Technologies Inc stock (544.08 JPY) is 20% less than its price (682 JPY).
Human Metabolome Technologies Inc stock (482.84 JPY) is 29% less than its price (682 JPY). Open DCF Valuation
Human Metabolome Technologies Inc stock (605.32 JPY) is 11% less than its price (682 JPY). Open Relative Valuation
Human Metabolome Technologies Inc.
Human Metabolome Technologies Inc's Revenue has grown by 2% over the past 12 months.
Human Metabolome Technologies Inc has positive Operating Income for the last twelve months.
Human Metabolome Technologies Inc's Revenue has been growing by 3% per year for the last 3 years.
Human Metabolome Technologies Inc has positive Net Income for the last twelve months.
Human Metabolome Technologies Inc's ROE (Return on Equity) for the past 12 months is positive and is equal to 17%.
Human Metabolome Technologies Inc has positive three-year average ROE (Return on Equity): 13%. The company is efficient at transforming stockholders' equity into net income.
Human Metabolome Technologies Inc has positive Free Cash Flow for the last twelve months.
Human Metabolome Technologies Inc's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 34%.
Human Metabolome Technologies Inc's ROE (Return on Equity) has significantly increased in the last 3 years from -3% to 17%.
Human Metabolome Technologies Inc's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -12% to 34%.
Human Metabolome Technologies Inc has very high three-year average ROIC (Return on Invested Capital): 27%. The company is very efficient at using invested capital to generate operating income.
Human Metabolome Technologies Inc has positive Gross Profit for the last twelve months.
Human Metabolome Technologies Inc's D/E (Debt to Equity) is very low and is equal to 0.12.
Human Metabolome Technologies Inc's short-term assets (2B JPY) exceed its short-term liabilties (411m JPY).
Human Metabolome Technologies Inc's long-term assets (2B JPY) exceed its long-term liabilties (432m JPY).
Human Metabolome Technologies Inc has negative Net Debt. This means that the company has more cash and short-term investments (1B JPY) than debt (208m JPY).
Human Metabolome Technologies Inc's Altman Z-Score is very high and is equal to 6.43.
Human Metabolome Technologies Inc earns more than enough operating income (198m JPY) to safely cover interest payments on its debt (2m JPY).
Valuation Backtest
Human Metabolome Technologies Inc
Run backtest to discover the historical profit from buying and selling
Human Metabolome Technologies Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Human Metabolome Technologies Inc
Balance Sheet Decomposition
Human Metabolome Technologies Inc
| Current Assets | 1.8B |
| Cash & Short-Term Investments | 1.4B |
| Receivables | 308.4m |
| Other Current Assets | 59.4m |
| Non-Current Assets | 409.4m |
| PP&E | 256.5m |
| Intangibles | 20.1m |
| Other Non-Current Assets | 132.9m |
| Current Liabilities | 411.3m |
| Accounts Payable | 10m |
| Accrued Liabilities | 44.5m |
| Short-Term Debt | 200m |
| Other Current Liabilities | 156.8m |
| Non-Current Liabilities | 20.5m |
| Long-Term Debt | 8m |
| Other Non-Current Liabilities | 12.6m |
Earnings Waterfall
Human Metabolome Technologies Inc
|
Revenue
|
1.3B
JPY
|
|
Cost of Revenue
|
-462.1m
JPY
|
|
Gross Profit
|
859.5m
JPY
|
|
Operating Expenses
|
-661.3m
JPY
|
|
Operating Income
|
198.2m
JPY
|
|
Other Expenses
|
84.4m
JPY
|
|
Net Income
|
282.6m
JPY
|
Free Cash Flow Analysis
Human Metabolome Technologies Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Human Metabolome Technologies Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Human Metabolome Technologies Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Human Metabolome Technologies Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Human Metabolome Technologies Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Human Metabolome Technologies Inc
Shareholder Return
Price
Human Metabolome Technologies Inc
| Average Annual Return | -6.6% |
| Standard Deviation of Annual Returns | 9.64% |
| Max Drawdown | -67% |
| Market Capitalization | 4B JPY |
| Shares Outstanding | 5 915 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Human Metabolome Technologies Inc
Country
Industry
Market Cap
Dividend Yield
Description
Human Metabolome Technologies, Inc. engages in the business of diagnostic technology and medical products. The company is headquartered in Tsuruoka-Shi, Yamagata-Ken and currently employs 69 full-time employees. The company went IPO on 2013-12-24. The firm operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.
Contact
IPO
Employees
Officers
The intrinsic value of one
Human Metabolome Technologies Inc
stock under the Base Case scenario is
544.08
JPY.
Compared to the current market price of 682 JPY,
Human Metabolome Technologies Inc
is
Overvalued by 20%.
You don't have any saved screeners yet
